In 2001, Schering-Plough developed one of the first small molecule CCR5 antagonists,  SCH-C or SCH 351125, which inhibited replication of a number of HIV-1 isolates that used CCR5 as a coreceptor for binding.<ref name=Palani>{{cite journal |vauthors=Palani A, Shapiro S, Clader JW, Greenlee WJ, Cox K, Strizki J, Endres M, Baroudy BM |title=Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection. |journal= J Med Chem |volume=44 |issue=21 |pages=3339–42 |year=2001 |pmid=11585437 |doi=10.1021/jm015526o }}</ref>  However, SCH-C caused a modest but dose-dependent prolongation of the corrected cardiac QT interval ([[QTc]]),<ref name=Strizki>{{cite journal |vauthors=Strizki JM, Tremblay C, Xu S, Wojcik L, Wagner N, Gonsiorek W, Hipkin RW, Chou CC, Pugliese-Sivo C, Xiao Y, Tagat JR, Cox K, Priestley T, Sorota S, Huang W, Hirsch M, Reyes GR, Baroudy BM |title=Discovery and Characterization of Vicriviroc (SCH 417690), a CCR5 Antagonist with Potent Activity against Human Immunodeficiency Virus Type 1 |journal=Antimicrobial Agents and Chemotherapy|volume=49 |issue=12 |pages=4911–4919 |year=2005 |pmid=16304152 |doi=10.1128/AAC.49.12.4911-4919.2005 |pmc=1315929}}</ref> leading to examination of alternative compounds whose antiviral and pharmacokinetic properties exceeded those of first-generation compounds like SCH-C.  Vicriviroc was discovered in high-throughput screening and structure-activity relationships (SAR) analysis.<ref name=Tagat>{{cite journal  |vauthors=Tagat JR, McCombie SW, Nazareno D, Labroli MA, Xiao Y, Steensma RW, Strizki JM, Baroudy BM, Cox K, etal |title=Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist |journal=J Med Chem |volume=47 |issue=10 |pages=2405–8 |year=2004 |pmid=15115380 |doi=10.1021/jm0304515}}</ref> When compared with SCH-C, vicriviroc consistently and more actively inhibits viral replication, binds with higher affinity to CCR5 than SCH-C, and possesses a lower affinity for the [[HERG|human ether-a-go-go-related gene]] transcript ion channel, which may suggest a lower risk of cardiac effects.<ref name=Strizki/>
